Skip to content
MARKETS / NASDAQ / AXSM
NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP

Axsome Therapeutics, Inc. AXSM

12 fiscal years on record · USD · FY2025 reported · SEC filings only
$638.5M
▲ 65.5% YoY
$-183.2M
$-93.9M
In brief

What this company does

It markets three FDA-approved commercial products for central nervous system conditions: AUVELITY, for major depressive disorder; SUNOSI, for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy; and SYMBRAVO, for the acute treatment of migraine with or without aura in adults. Total revenues from its three commercial products totaled $638.5 million for 2025. As of February 16, 2026, it had 925 full-time employees. Its lead product candidate, AXS-05, a combination of dextromethorphan and bupropion, is currently being developed for the treatment of Alzheimer's disease agitation and smoking cessation. It was incorporated in Delaware in January 2012, with offices located at One World Trade Center, New York, New York.

Written from the business description in Axsome Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 23 February 2026. Every sentence was checked against that document before publication.

Growth
USD 638.5M
Revenue, FY2025 · full 12-year series below
Revenue $M Net income $M
FY2025 · Revenue 638.5 · Net income -183.2
250.0M500.0M-100.0M-200.0M2014201620182020202220242025
Compound annual growth
+133.7%
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−29 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -26.1% · Net -28.7%
-100%-200%-300%2014201620182020202220242025
ROE
FY2025 · ROE -252.1%
-100%-200%-300%2014201620182020202220242025

Each USD of equity lost 252 cents this year.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -93.9
-50M-100M2014201620182020202220242025

Total assetsUSD 689.8M
EquityUSD 88.3M
CashUSD 322.9M
Gross debtUSD 187.7M
Net debtUSD -135.2M
Current ratio1.55×

The company holds more cash than debt.

The 12-year record
12 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202520242023202220212020201920182017201620152014
Revenue $B0.60.40.30.1········
Operating income $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0·
Income tax $B−0.00.00.00.00.00.00.00.00.00.0··
Net income $B−0.2−0.3−0.2−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0·
EPS, diluted $−3.68−5.99−5.27−4.60−3.47−2.77−2.01−1.15−1.27−1.42−1.02−0.66
Dividend / sh $············
Payout %············
ROE %−252.1−231.6−159.2−299.0−201.5−70.4−76.1−350.8−151.2−80.0−56.5·
Shares out B0.050.050.050.040.040.040.040.030.030.020.02·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 46 reconciliationsAUDITED

Reconciled in 12 of 19 fiscal years. 45 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2014

Share this section

Download image